Nuvalent, Inc. (NUVL)

70.65 +1.77 (+2.57%) 收市：04:00PM EDT

Nuvalent, Inc.

One Broadway
14th Floor
Cambridge, MA 02142
United States
857 357 7000
https://www.nuvalent.com

版塊: Healthcare
行業: Biotechnology
全職員工: 92

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. James R. Porter Ph.D.	CEO, President & Director	998.02k	無	1976
Prof. Matthew D. Shair Ph.D.	Founder, Head of Scientific Advisory Board & Director	235k	無	1969
Dr. Christopher D. Turner M.D.	Chief Medical Officer	714.26k	無	1969
Dr. Benjamin Lane Ph.D.	Senior Vice President of Technical Operations	無	無	無
Ms. Deborah Ann Miller J.D., Ph.D.	Chief Legal Officer & Secretary	595.96k	無	1976
Mr. Matthew Metivier	Senior Vice President of Human Resources	無	無	無
Ms. Darlene Noci	Chief Development Officer	無	無	1978
Mr. Henry Pelish Ph.D.	Senior Vice President of Drug Discovery	無	無	無
Mr. John Soglia Ph.D.	Senior Vice President of Translational Development	無	無	無
Ms. Perrin Wilson B.S., Ph.D.	Senior Vice President of Business Development & Strategy	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

公司管治

截至 2024年4月29日 止，Nuvalent, Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：7；董事會：7；股東權利：10；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。